These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25023344)

  • 1. Molecular analysis for therapy choice: NCI MATCH.
    Conley BA; Doroshow JH
    Semin Oncol; 2014 Jun; 41(3):297-9. PubMed ID: 25023344
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular genetic tumor markers and their analysis for diagnosis and therapy of cancer patients].
    Ianov IuK; Novik AA; Belokhvostov AS
    Klin Med (Mosk); 1999; 77(11):4-9. PubMed ID: 10635622
    [No Abstract]   [Full Text] [Related]  

  • 3. Biology-driven phase II trials: what is the optimal model for molecular selection?
    Andre F; Delaloge S; Soria JC
    J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
    [No Abstract]   [Full Text] [Related]  

  • 4. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 5. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.
    Taube SE; Gion M; Schilsky RL
    Expert Rev Mol Diagn; 2004 Jul; 4(4):431-3. PubMed ID: 15225090
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing cancer with a blood draw.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(23):1774-5. PubMed ID: 23213181
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biomarker for molecular targeting therapy against renal cell carcinoma].
    Mizuno R; Oya M
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
    [No Abstract]   [Full Text] [Related]  

  • 8. Combining targeted drugs to stop resistant tumors.
    Kaiser J
    Science; 2011 Mar; 331(6024):1542-5. PubMed ID: 21436437
    [No Abstract]   [Full Text] [Related]  

  • 9. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers as molecular targets of drug interventions.
    Smith JJ; Dunn BK
    Semin Oncol Nurs; 2012 May; 28(2):109-15. PubMed ID: 22542318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.
    Zitvogel L; Kepp O; Aymeric L; Ma Y; Locher C; Delahaye NF; André F; Kroemer G
    Cancer Res; 2010 Dec; 70(23):9538-43. PubMed ID: 21098713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness of cancer drug treatments].
    Akazawa M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():706-12. PubMed ID: 25831852
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer and natural selection.
    Fillon M
    J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180
    [No Abstract]   [Full Text] [Related]  

  • 14. NCI-MATCH trial pushes cancer umbrella trial paradigm.
    Mullard A
    Nat Rev Drug Discov; 2015 Aug; 14(8):513-5. PubMed ID: 26228747
    [No Abstract]   [Full Text] [Related]  

  • 15. [Targeted therapy: old and new possibilities].
    Hochhaus A; Lüftner D; Mackensen A
    Onkologie; 2013; 36 Suppl 5():2-11. PubMed ID: 23921800
    [No Abstract]   [Full Text] [Related]  

  • 16. Epistatic interactions and drug response.
    Weigelt B; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From traditional molecular biology to network oncology.
    Ziogas DE; Katsios C; Roukos DH
    Future Oncol; 2011 Feb; 7(2):155-9. PubMed ID: 21345133
    [No Abstract]   [Full Text] [Related]  

  • 18. Identifying cancer mutations as therapeutic targets.
    Azvolinsky A
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25122735
    [No Abstract]   [Full Text] [Related]  

  • 19. "Marking" of cancer: the road to clinical decision making.
    Sudoyo AW
    Acta Med Indones; 2010 Jan; 42(1):1. PubMed ID: 20737744
    [No Abstract]   [Full Text] [Related]  

  • 20. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?
    Sargent D
    Oncologist; 2010; 15 Suppl 1():19-23. PubMed ID: 20237213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.